Forest’s Namenda Gets “Not Approvable” Letter For Mild Alzheimer’s Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm blames supplementary studies – which found numerical improvement for the memantine cohort but failed to meet statistical significance – for the denial.